1. Home
  2. TNGX vs ESGRP Comparison

TNGX vs ESGRP Comparison

Compare TNGX & ESGRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • ESGRP
  • Stock Information
  • Founded
  • TNGX 2014
  • ESGRP N/A
  • Country
  • TNGX United States
  • ESGRP Bermuda
  • Employees
  • TNGX N/A
  • ESGRP 805
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • ESGRP Property-Casualty Insurers
  • Sector
  • TNGX Health Care
  • ESGRP Finance
  • Exchange
  • TNGX Nasdaq
  • ESGRP Nasdaq
  • Market Cap
  • TNGX 735.0M
  • ESGRP N/A
  • IPO Year
  • TNGX N/A
  • ESGRP N/A
  • Fundamental
  • Price
  • TNGX $6.64
  • ESGRP $20.82
  • Analyst Decision
  • TNGX Strong Buy
  • ESGRP
  • Analyst Count
  • TNGX 8
  • ESGRP 0
  • Target Price
  • TNGX $15.14
  • ESGRP N/A
  • AVG Volume (30 Days)
  • TNGX 885.7K
  • ESGRP N/A
  • Earning Date
  • TNGX 11-06-2024
  • ESGRP N/A
  • Dividend Yield
  • TNGX N/A
  • ESGRP N/A
  • EPS Growth
  • TNGX N/A
  • ESGRP N/A
  • EPS
  • TNGX N/A
  • ESGRP N/A
  • Revenue
  • TNGX $42,509,000.00
  • ESGRP N/A
  • Revenue This Year
  • TNGX $18.15
  • ESGRP N/A
  • Revenue Next Year
  • TNGX N/A
  • ESGRP N/A
  • P/E Ratio
  • TNGX N/A
  • ESGRP N/A
  • Revenue Growth
  • TNGX 26.16
  • ESGRP N/A
  • 52 Week Low
  • TNGX $6.33
  • ESGRP N/A
  • 52 Week High
  • TNGX $13.01
  • ESGRP N/A
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 37.15
  • ESGRP 64.69
  • Support Level
  • TNGX $6.83
  • ESGRP $19.91
  • Resistance Level
  • TNGX $7.47
  • ESGRP $20.20
  • Average True Range (ATR)
  • TNGX 0.37
  • ESGRP 0.37
  • MACD
  • TNGX 0.11
  • ESGRP 0.17
  • Stochastic Oscillator
  • TNGX 27.31
  • ESGRP 81.45

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

About ESGRP Enstar Group Limited Depositary Shares Each Representing 1/1000th of an interest in Preference Shares

Enstar Group Ltd is a (re)insurance group that offers capital release solutions through its network of group companies. It seeks to create value by managing (re)insurance companies and portfolios of (re)insurance and other liability businesses in run-off and striving to generate an attractive risk-adjusted return from its investment portfolio. Its operations are through four reportable segments: Run-off, Assumed Life, Investments, and Legacy Underwriting.

Share on Social Networks: